Global
About
Development milestones Mission&Vision Founder Research Achievement
Technology Platforms
Single domain antibody Five core technology platforms
Pipeline
Business cooperation
Product Out-Licensing Co-Development
Career development
Our Story Social Recruitment
News
Company News Media
Contact Us
Company Address Online Message
×
Pipeline

Progress and introduction
of main products

Product pipeline
Product layout focuses on advantages and products are rapidly promoted
Respiratory
Project
Disease field
Indication
Route of admin
Clinical trial area
Preclinical
Discovery
CMC
Toxicological study
IND
Phase I
Phase II
Phase III
Commercial Rights
LQ036
Autoimmune
EOS Asthma
Inhaled
Phase I SAD completed
Global
EOS Asthma
Inhaled
Chinese clinical IIa completed, IIb ongoing
Global
COPD
Inhaled
IND approved in Sep 2023
Global
LQ036
More
LQ043H
Autoimmune
Non-EOS Asthma
Inhaled
China: Clinical Ib is currently underway
Global
COPD
Inhaled
To be planned
Global
LQ043H
More
LQ059
Autoimmune
CF
Inhaled
CMC
Global
Inflammation
Project
Disease field
Indication
Route of admin
Clinical trial area
Preclinical
Discovery
CMC
Toxicological study
IND
Phase I
Phase II
Phase III
Commercial Rights
LQ073
IBD
SC
CMC
Global
LQ080
Autoimmune
IBD
SC
Leads optimization
Global
Synthetic cytokine
Project
Disease field
Indication
Route of admin
Clinical trial area
Preclinical
Discovery
CMC
Toxicological study
IND
Phase I
Phase II
Phase III
Commercial Rights
LQ058
Immuno-Oncology
Oncology
SC
Leads optimization
Global
Ophthalmic
Project
Disease field
Indication
Route of admin
Clinical trial area
Preclinical
Discovery
CMC
Toxicological study
IND
Phase I
Phase II
Phase III
Commercial Rights
LQ015
Ophthalmic
AMD
Eye drops
CMC
Global